SOHO 2022 Tenth Annual Meeting

 

SOHO 2022 Tenth Annual Meeting
A

SOHO 2022: AGILE - A Phase 3, Global, Randomized, Double-Blind Study of Ivo + Aza vs. Placebo + Aza in Newly Diagnosed AML With an IDH1 Mutation

By SOHO 2022 Tenth Annual Meeting FEATURING Adolfo de la Fuente, Courtney D. DiNardo
By SOHO 2022 Tenth Annual Meeting FEATURING Adolfo de la Fuente, Courtney D. DiNardo
0 views
October 14, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
Leukemia
06:06
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Characteristics of Patients With Myelofibrosis Taking Rux…

Feat. L. Masarova
16:50
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Role of ddPCR in CML Today

Feat. J. Radich, S. Soverini
15:48
SOHO 2022 Tenth Annual Meeting

SOHO 2022: State of the Art in CML

Feat. M. Deininger, G. Saglio
08:51
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Long-Term Outcomes After Haplo-SCT for Hematologic Malign…

Feat. S. Saengboon
09:22
SOHO 2022 Tenth Annual Meeting

GLOW Study - First Prospective Data on MRD Outcomes After Fixed-Dura…

Feat. C. Owen
09:54
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: CML

Feat. T. Hughes
08:27
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: CLL

Feat. F. Cymbalista
12:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: AML

Feat. H. Kantarjian
10:33
Lori Muffly

Next Questions: ALL

11:20
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Orca-T Results in High GVHD-Free and Relapse-Free Surviva…

Feat. S. Srour
15:25
SOHO 2022 Tenth Annual Meeting

Supportive Therapy in CLL

Feat. C. Sun
14:10
SOHO 2022 Tenth Annual Meeting

CLL - Real World Data With Small Molecules

Feat. F. Cymbalista
14:13
SOHO 2022 Tenth Annual Meeting

CLL DEBATE: How Many Drugs Are Needed in 1L CLL?

Feat. A. Mato
15:03
SOHO 2022 Tenth Annual Meeting

CLL DEBATE: Combination Small Molecules vs. Sequencing in CLL - Pro …

Feat. J. Brown
13:53
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Covalent BTK Inhibitors - How Do They Compare in CLL?

Feat. J. Byrd
15:10
SOHO 2022 Tenth Annual Meeting

Clinical Significance of B-Cell Receptor Stereotypy in CLL

Feat. K. Stamatopoulos
10:34
SOHO 2022 Tenth Annual Meeting

SOHO 2022: PACE and OPTIC Trials - Dose Modification Dynamics of Pon…

Feat. H. Kantarjian
16:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Asciminib or Ponatinib for Multiresistant CML Patients?

Feat. J. Cortés
14:57
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Immunotherapy - The Way Forward to Maximize TFR in CML?

Feat. D. Rea
13:34
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Beyond TKI Therapy in CML

Feat. M. Copland
09:52
SOHO 2022 Tenth Annual Meeting

SOHO 2022: AGILE - A Phase 3, Global, Randomized, Double-Blind Study…

Feat. A. de la Fuente, C. DiNardo
16:04
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Emerging CAR T-Cell Therapy Approaches in AML

Feat. S. Kenderian
15:39
SOHO 2022 Tenth Annual Meeting

SOHO 2022 AML DEBATE: Is MRD More Prognostic Than Initial Presentati…

Feat. C. Lindsley
16:37
SOHO 2022 Tenth Annual Meeting

SOHO 2022 AML DEBATE: Is MRD More Prognostic Than Initial Presentati…

Feat. M. Heuser
14:41
Farhad Ravandi

Is the Future of AML Therapy All Oral?

14:50
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Non-Intensive Treatment of Elderly/Unfit Patients With AML

Feat. T. Kadia
15:45
SOHO 2022 Tenth Annual Meeting

SOHO 2022: How Do We Overcome Resistance to Venetoclax in AML

Feat. M. Konopleva
15:21
SOHO 2022 Tenth Annual Meeting

SOHO 2022: FLT3-Mutated AML - Triplet vs. Doublet Therapy

Feat. E. Wang
15:13
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Menin Inhibitors in AML

Feat. E. Stein
17:07
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Novel Chemotherapy Can Eliminate the Need for Transplant …

Feat. N. Short
11:49
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Certain Patients With ALL Still Need a Transplant

Feat. J. Ribera, P. Scheinberg
15:52
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Approach to ALL in the Elderly

Feat. M. Luskin
13:46
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Management of Ph+ ALL in 2022

Feat. E. Jabbour
06:35
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Phase II Study of Blinatumomab in Combination With Ponati…

Feat. F. Haddad
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Dual Targeted CAR T-Cells for ALL

Feat. N. Frey
12:49
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Approach to Ph-Like ALL

Feat. E. Curran
16:13
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Blinatumomab in Pediatric ALL

Feat. S. Cooper
12:06
Catherine Coombs

New BTKi in CLL

09:23
SOHO 2022 Tenth Annual Meeting

Novel Agents in CLL

Feat. A. Danilov
11:07
SOHO 2022 Tenth Annual Meeting

SOHO 2022: BCL2i in CLL

Feat. A. Chanan-Khan
08:48
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Childhood CML

Feat. F. Millot
20:12
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Assessment and Management of TKI-Related AOEs in CML

Feat. G. Saglio
13:09
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Non BCR-ABL Mutations in CML - Do They Matter?

Feat. S. Soverini
15:43
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Advances in ALL Diagnosis and Treatment - The NOPHO Exper…

Feat. K. Schmiegelow
09:08
Selina Luger

Approaches to and Use of MRD in ALL

11:13
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Allogeneic CAR T-Cells in ALL

Feat. N. Jain
12:26
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Is TP53-Mutated AML the Same Disease as TP53-Mutated MDS?

Feat. P. Valk
19:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Update on CD47 Targeting Antibodies

Feat. N. Daver
20:35
SOHO 2022 Tenth Annual Meeting

SOHO 2022: What Is the Best Strategy for Therapy-Related AML?

Feat. P. Desai